Literature DB >> 17496437

[TP53 mutations and molecular epidemiology].

Kazunori Otsuka1, Chikashi Ishioka.   

Abstract

Tumor suppressor p53 protein is activated by a variety of cellular stresses through several pathways and transactivates its downstream genes, including regulators of cell cycle, apoptosis and DNA repair. The loss of p53 function by TP53 gene mutations therefore fails to activate these genes and is thought to be a critical cause of carcinogenesis and/or tumor progression. TP53 is one of the most frequently mutated genes in human cancer. TP53 mutations are found in about 50% of human cancers, although the frequency of TP53 mutations differs among tumor types. However, the degree of functional disorder of mutant p53 varies according to the type of TP53 mutation. And the effects of p53 on cancer formation and/or progression are influenced by the degree of p53 dysfunction. So it is important to analyze the effects of TP53 mutations carefully according to the oncogenicity of each mutation from the molecular epidemiological point of view. Here, together with some cautions needed for analyzing and interpreting the significance of TP53 gene mutations, we present some examples of the identified specific mutation spectrum and the correlation between the prognosis and TP53 mutation in some cancers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17496437

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  3 in total

1.  LIN28B inhibition sensitizes cells to p53-restoring PPI therapy through unleashed translational suppression.

Authors:  Jiahao Shi; Xiaoliang Jin; Yihao Wang; Tianyu Zhu; Dongmei Zhang; Qian Li; Xiaomin Zhong; Yaqi Deng; Jianfeng Shen; Xianqun Fan
Journal:  Oncogenesis       Date:  2022-07-02       Impact factor: 6.524

2.  Exposure to depleted uranium does not alter the co-expression of HER-2/neu and p53 in breast cancer patients.

Authors:  Mais M Al-Mumen; Asad A Al-Janabi; Alaa S Jumaa; Kaswer M Al-Toriahi; Akeel A Yasseen
Journal:  BMC Res Notes       Date:  2011-03-29

3.  Heterochronic triple primary malignancies with Epstein-Barr virus infection and tumor protein 53 gene mutation: A case report and review of literature.

Authors:  Wen-Xia Peng; Xin Liu; Qi-Feng Wang; Xiao-Yan Zhou; Zhi-Guo Luo; Xi-Chun Hu
Journal:  World J Clin Cases       Date:  2021-02-16       Impact factor: 1.337

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.